Nutriband Reports Record Q1 Revenue, Advances Abuse-Deterrent Opioid Patch Development
TL;DR
Nutriband (NASDAQ: NTRB) reported 63% revenue increase, focusing on shareholder value by expanding kinesiology tape production and retail presence.
Nutriband is developing AVERSA Fentanyl patch with abuse-deterrent technology, emphasizing prevention of drug abuse, misuse, diversion, and accidental exposure.
Nutriband's AVERSA technology aims to make the world better by preventing drug abuse and promoting safer transdermal drug delivery methods.
Nutriband partners with Kindeva for AVERSA Fentanyl patch, projected to achieve $80-200 million U.S. sales annually, enhancing drug delivery technology.
Found this article helpful?
Share it with your network and spread the knowledge!
Nutriband Inc. reported first-quarter revenues of $667,000, representing a 63% year-over-year increase, driven by expanded kinesiology tape production and growing retail presence across major national retailers including Target, Walmart, Walgreens, and CVS.
The pharmaceutical development company is making substantial strides in advancing its AVERSA Fentanyl project, an abuse-deterrent transdermal opioid patch designed to mitigate potential drug misuse. Through a strategic partnership with Kindeva Drug Delivery, Nutriband will share development costs and receive milestone payments as the product progresses toward regulatory approval.
Industry analysts project the AVERSA Fentanyl patch could generate peak annual U.S. sales between $80 million and $200 million, representing a significant market opportunity. The product's abuse-deterrent technology aims to prevent misuse, diversion, and accidental exposure of potentially dangerous pharmaceutical substances.
Nutriband's approach addresses critical healthcare challenges by developing innovative pharmaceutical delivery systems that prioritize patient safety while maintaining effective pain management strategies. The company's commitment to developing transdermal pharmaceutical products with enhanced safety features positions it as a potential leader in responsible medication development.
Curated from InvestorBrandNetwork (IBN)
